drugset / Trial / NCT01515345

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

NCT01515345

Phase 3 Completed 1008 enrolled Kaiser Franz Josef Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).

Timeline

Start
2011-07
Primary completion
2013-01
Completion
2013-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg
Subject Prasugrel Small molecule 10 mg
Subject Ticagrelor Small molecule 90 mg